{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T05:13:22Z","timestamp":1783487602542,"version":"3.55.0"},"reference-count":39,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:00:00Z","timestamp":1778889600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Special Research Project on Foot and Ankle Disorders from the China Association of Chinese Medicine","award":["CACM-2025-GSKY03-C2"],"award-info":[{"award-number":["CACM-2025-GSKY03-C2"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Musculoskelet Disord"],"DOI":"10.1186\/s12891-026-09965-w","type":"journal-article","created":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T00:34:26Z","timestamp":1778891666000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Pharmacological treatment for Charcot neuroarthropathy: a systematic review"],"prefix":"10.1186","volume":"27","author":[{"given":"Liang","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qiong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmou","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,16]]},"reference":[{"issue":"9","key":"9965_CR1","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.1007\/s00125-013-2961-6","volume":"56","author":"LJ Sanders","year":"2013","unstructured":"Sanders LJ, Edmonds ME, Jeffcoate WJ. Who was first to diagnose and report neuropathic arthropathy of the foot and ankle: Jean-Martin Charcot or Herbert William Page? Diabetologia. 2013;56(9):1873\u20137.","journal-title":"Diabetologia"},{"issue":"1","key":"9965_CR2","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.cpm.2007.10.001","volume":"25","author":"RG Frykberg","year":"2008","unstructured":"Frykberg RG, Belczyk R. Epidemiology of the Charcot foot. Clin Podiatr Med Surg. 2008;25(1):17\u201328. v.","journal-title":"Clin Podiatr Med Surg"},{"issue":"6","key":"9965_CR3","doi-asserted-by":"publisher","first-page":"796","DOI":"10.2337\/diacare.23.6.796","volume":"23","author":"J Fabrin","year":"2000","unstructured":"Fabrin J, Larsen K, Holstein PE. Long-term follow-up in diabetic Charcot feet with spontaneous onset. Diabetes Care. 2000;23(6):796\u2013800.","journal-title":"Diabetes Care"},{"issue":"3","key":"9965_CR4","doi-asserted-by":"publisher","first-page":"365","DOI":"10.1055\/s-0030-1254525","volume":"14","author":"IG Schoots","year":"2010","unstructured":"Schoots IG, Slim FJ, Busch-Westbroek TE, Maas M. Neuro-osteoarthropathy of the foot-radiologist: friend or foe? Semin Musculoskelet Radiol. 2010;14(3):365\u201376.","journal-title":"Semin Musculoskelet Radiol"},{"issue":"8","key":"9965_CR5","doi-asserted-by":"publisher","first-page":"1170","DOI":"10.1016\/j.fas.2022.08.004","volume":"28","author":"K Yammine","year":"2022","unstructured":"Yammine K, Boulos K, Assi C, Hayek F. Amputation and mortality frequencies associated with diabetic Charcot foot arthropathy: a meta-analysis. Foot Ankle Surg. 2022;28(8):1170\u20136.","journal-title":"Foot Ankle Surg"},{"key":"9965_CR6","first-page":"100239","volume":"22","author":"D Dardari","year":"2020","unstructured":"Dardari D. An overview of Charcot\u2019s neuroarthropathy. J Clin Transl Endocrinol. 2020;22:100239.","journal-title":"J Clin Transl Endocrinol"},{"issue":"7","key":"9965_CR7","doi-asserted-by":"publisher","first-page":"1691","DOI":"10.2337\/dc21-2508","volume":"45","author":"W Jeffcoate","year":"2022","unstructured":"Jeffcoate W, Game F. The Charcot Foot Reflects a Response to Injury That Is Critically Distorted by Preexisting Nerve Damage: An Imperfect Storm. Diabetes Care. 2022;45(7):1691\u20137.","journal-title":"Diabetes Care"},{"issue":"9502","key":"9965_CR8","doi-asserted-by":"publisher","first-page":"2058","DOI":"10.1016\/S0140-6736(05)67029-8","volume":"366","author":"WJ Jeffcoate","year":"2005","unstructured":"Jeffcoate WJ, Game F, Cavanagh PR. The role of proinflammatory cytokines in the cause of neuropathic osteoarthropathy (acute Charcot foot) in diabetes. Lancet. 2005;366(9502):2058\u201361.","journal-title":"Lancet"},{"key":"9965_CR9","doi-asserted-by":"publisher","first-page":"5647981","DOI":"10.1155\/2018\/5647981","volume":"2018","author":"RB Jansen","year":"2018","unstructured":"Jansen RB, Christensen TM, Bulow J, Rordam L, Jorgensen NR, Svendsen OL. Markers of Local Inflammation and Bone Resorption in the Acute Diabetic Charcot Foot. J Diabetes Res. 2018;2018:5647981.","journal-title":"J Diabetes Res"},{"issue":"10","key":"9965_CR10","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1177\/107110070602701007","volume":"27","author":"JF Baumhauer","year":"2006","unstructured":"Baumhauer JF, O\u2019Keefe RJ, Schon LC, Pinzur MS. Cytokine-induced osteoclastic bone resorption in charcot arthropathy: an immunohistochemical study. Foot Ankle Int. 2006;27(10):797\u2013800.","journal-title":"Foot Ankle Int"},{"issue":"6","key":"9965_CR11","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s00125-008-0992-1","volume":"51","author":"G Mabilleau","year":"2008","unstructured":"Mabilleau G, Petrova NL, Edmonds ME, Sabokbar A. Increased osteoclastic activity in acute Charcot\u2019s osteoarthropathy: the role of receptor activator of nuclear factor-kappaB ligand. Diabetologia. 2008;51(6):1035\u201340.","journal-title":"Diabetologia"},{"key":"9965_CR12","doi-asserted-by":"crossref","unstructured":"Greco T, Mascio A, Comisi C, et al. RANKL-RANK-OPG Pathway in Charcot Diabetic Foot: Pathophysiology and Clinical-Therapeutic Implications. Int J Mol Sci. 2023;24(3):3014.","DOI":"10.3390\/ijms24033014"},{"issue":"1","key":"9965_CR13","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1111\/j.1464-5491.1994.tb00225.x","volume":"11","author":"PL Selby","year":"1994","unstructured":"Selby PL, Young MJ, Boulton AJM. Bisphosphonates - a New Treatment for Diabetic Charcot Neuroarthropathy. Diabet Med. 1994;11(1):28\u201331.","journal-title":"Diabet Med"},{"issue":"6","key":"9965_CR14","doi-asserted-by":"publisher","first-page":"105241","DOI":"10.1016\/j.jbspin.2021.105241","volume":"88","author":"S Carves","year":"2021","unstructured":"Carves S, Bourgeon-Ghittori M, Henry J, et al. Denosumab in active Charcot neuro-osteoarthropathy of the foot. Joint bone spine. 2021;88(6):105241.","journal-title":"Joint bone spine"},{"issue":"6","key":"9965_CR15","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.2337\/dc06-0376","volume":"29","author":"R Bem","year":"2006","unstructured":"Bem R, Jirkovsk\u00e1 A, Fejfarov\u00e1 V, Skibov\u00e1 J, Jude EB. Intranasal calcitonin in the treatment of acute Charcot neuroosteoarthropathy: a randomized controlled trial. Diabetes Care. 2006;29(6):1392\u20134.","journal-title":"Diabetes Care"},{"issue":"7","key":"9965_CR16","doi-asserted-by":"publisher","first-page":"1613","DOI":"10.2337\/dc21-0008","volume":"44","author":"NL Petrova","year":"2021","unstructured":"Petrova NL, Donaldson NK, Bates M, et al. Effect of recombinant human parathyroid hormone (1\u201384) on resolution of active charcot neuro-osteoarthropathy in diabetes: A randomized, double-blind, placebo-controlled study. Diabetes Care. 2021;44(7):1613\u201321.","journal-title":"Diabetes Care"},{"issue":"6","key":"9965_CR17","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/s00592-020-01664-9","volume":"58","author":"A Rastogi","year":"2021","unstructured":"Rastogi A, Bhansali A, Jude EB. Efficacy of medical treatment for Charcot neuroarthropathy: a systematic review and meta-analysis of randomized controlled trials. Acta Diabetol. 2021;58(6):687\u201396.","journal-title":"Acta Diabetol"},{"key":"9965_CR18","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","volume":"339","author":"D Moher","year":"2009","unstructured":"Moher D, Liberati A, Tetzlaff J, Altman DG, Group P. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.","journal-title":"BMJ"},{"key":"9965_CR19","doi-asserted-by":"publisher","first-page":"l4898","DOI":"10.1136\/bmj.l4898","volume":"366","author":"JAC Sterne","year":"2019","unstructured":"Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898.","journal-title":"BMJ"},{"issue":"11","key":"9965_CR20","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1007\/s001250100008","volume":"44","author":"EB Jude","year":"2001","unstructured":"Jude EB, Selby PL, Burgess J, et al. Bisphosphonates in the treatment of Charcot neuroarthropathy: a double-blind randomised controlled trial. Diabetologia. 2001;44(11):2032\u20137.","journal-title":"Diabetologia"},{"issue":"3","key":"9965_CR21","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1055\/s-2008-1042425","volume":"40","author":"D Pitocco","year":"2008","unstructured":"Pitocco D, Collina MC, Musella T, et al. Interaction between IGF-1, inflammation, and neuropathy in the pathogenesis of acute Charcot neuroarthropathy: Lessons from alendronate therapy and future perspectives of medical therapy. Horm Metab Res. 2008;40(3):163\u20134.","journal-title":"Horm Metab Res"},{"issue":"7","key":"9965_CR22","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.2337\/dc11-0396","volume":"34","author":"T-K Pakarinen","year":"2011","unstructured":"Pakarinen T-K, Laine H-J, Maenpaa H, Mattila P, Lahtela J. The Effect of Zoledronic Acid on the Clinical Resolution of Charcot Neuroarthropathy A pilot randomized controlled trial. Diabetes Care. 2011;34(7):1514\u20136.","journal-title":"Diabetes Care"},{"issue":"12","key":"9965_CR23","doi-asserted-by":"publisher","first-page":"e185","DOI":"10.2337\/dc19-1659","volume":"42","author":"L Das","year":"2019","unstructured":"Das L, Bhansali A, Prakash M, Jude EB, Rastogi A. Effect of Methylprednisolone or Zoledronic Acid on Resolution of Active Charcot Neuroarthropathy in Diabetes: a Randomized, Double-Blind, Placebo-Controlled Study. Diabetes Care. 2019;42(12):e185\u20136.","journal-title":"Diabetes Care"},{"issue":"9","key":"9965_CR24","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1111\/1753-0407.12902","volume":"11","author":"A Rastogi","year":"2019","unstructured":"Rastogi A, Hajela A, Prakash M, et al. Teriparatide (recombinant human parathyroid hormone [1\u201334]) increases foot bone remodeling in diabetic chronic Charcot neuroarthropathy: a randomized double-blind placebo-controlled study. J diabetes. 2019;11(9):703\u201310.","journal-title":"J diabetes"},{"issue":"5","key":"9965_CR25","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.2337\/diacare.28.5.1214","volume":"28","author":"D Pitocco","year":"2005","unstructured":"Pitocco D, Ruotolo V, Caputo S, et al. Six-month treatment with alendronate in acute Charcot neuroarthropathy - A randomized controlled trial. Diabetes Care. 2005;28(5):1214\u20135.","journal-title":"Diabetes Care"},{"issue":"2","key":"9965_CR26","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/j.fas.2012.12.007","volume":"19","author":"TK Pakarinen","year":"2013","unstructured":"Pakarinen TK, Laine HJ, M\u00e4enp\u00e4\u00e4 H, K\u00e4h\u00f6nen M, Mattila P, Lahtela J. Effect of immobilization, off-loading and zoledronic acid on bone mineral density in patients with acute Charcot neuroarthropathy: a prospective randomized trial. Foot Ankle Surg. 2013;19(2):121\u20134.","journal-title":"Foot Ankle Surg"},{"issue":"11","key":"9965_CR27","doi-asserted-by":"publisher","first-page":"e0259224","DOI":"10.1371\/journal.pone.0259224","volume":"16","author":"L Das","year":"2021","unstructured":"Das L, Rastogi A, Jude EB, Prakash M, Dutta P, Bhansali A. Long-term foot outcomes following differential abatement of inflammation and osteoclastogenesis for active Charcot neuroarthropathy in diabetes mellitus. PLoS ONE. 2021;16(11):e0259224.","journal-title":"PLoS ONE"},{"issue":"4","key":"9965_CR28","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/j.cpm.2022.05.005","volume":"39","author":"M Schweitzer","year":"2022","unstructured":"Schweitzer M, Rockhill S. Conservative Management of Charcot Neuroarthropathy. Clin Podiatr Med Surg. 2022;39(4):585\u201394.","journal-title":"Clin Podiatr Med Surg"},{"key":"9965_CR29","doi-asserted-by":"crossref","unstructured":"Greco T, Mascio A, Comisi C, et al. RANKL-RANK-OPG Pathway in Charcot Diabetic Foot: Pathophysiology and Clinical-Therapeutic Implications. Int J Mol Sci. 2023;24(3):3031.","DOI":"10.3390\/ijms24033014"},{"issue":"2","key":"9965_CR30","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.abb.2008.03.018","volume":"473","author":"BF Boyce","year":"2008","unstructured":"Boyce BF, Xing L. Functions of RANKL\/RANK\/OPG in bone modeling and remodeling. Arch Biochem Biophys. 2008;473(2):139\u201346.","journal-title":"Arch Biochem Biophys"},{"key":"9965_CR31","doi-asserted-by":"crossref","unstructured":"Cheng CH, Chen LR, Chen KH. Osteoporosis Due to Hormone Imbalance: An Overview of the Effects of Estrogen Deficiency and Glucocorticoid Overuse on Bone Turnover. Int J Mol Sci. 2022;23(3):1376.","DOI":"10.3390\/ijms23031376"},{"issue":"5","key":"9965_CR32","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.beem.2018.05.003","volume":"32","author":"P Szulc","year":"2018","unstructured":"Szulc P. Bone turnover: Biology and assessment tools. Best Pract Res Clin Endocrinol Metab. 2018;32(5):725\u201338.","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"issue":"3","key":"9965_CR33","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1210\/endrev\/bnac031","volume":"44","author":"M Schini","year":"2023","unstructured":"Schini M, Vilaca T, Gossiel F, Salam S, Eastell R. Bone Turnover Markers: Basic Biology to Clinical Applications. Endocr Rev. 2023;44(3):417\u201373.","journal-title":"Endocr Rev"},{"issue":"2","key":"9965_CR34","doi-asserted-by":"publisher","first-page":"e11","DOI":"10.1016\/j.diabres.2011.12.029","volume":"96","author":"A Moura-Neto","year":"2012","unstructured":"Moura-Neto A, Fernandes TD, Zantut-Wittmann DE, et al. Charcot foot: skin temperature as a good clinical parameter for predicting disease outcome. Diabetes Res Clin Pract. 2012;96(2):e11\u201314.","journal-title":"Diabetes Res Clin Pract"},{"key":"9965_CR35","doi-asserted-by":"publisher","first-page":"204201882311604","DOI":"10.1177\/20420188231160406","volume":"14","author":"C Gooday","year":"2023","unstructured":"Gooday C, Hardeman W, Poland F, Woodburn J, Dhatariya K. Controversies in the management of active Charcot neuroarthropathy. Ther Adv Endocrinol Metab. 2023;14:20420188231160406.","journal-title":"Ther Adv Endocrinol Metab"},{"issue":"10329","key":"9965_CR36","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/S0140-6736(21)02646-5","volume":"399","author":"IR Reid","year":"2022","unstructured":"Reid IR, Billington EO. Drug therapy for osteoporosis in older adults. Lancet. 2022;399(10329):1080\u201392.","journal-title":"Lancet"},{"issue":"6","key":"9965_CR37","doi-asserted-by":"publisher","first-page":"225","DOI":"10.1177\/1759720X16670154","volume":"8","author":"B Langdahl","year":"2016","unstructured":"Langdahl B, Ferrari S, Dempster DW. Bone modeling and remodeling: potential as therapeutic targets for the treatment of osteoporosis. Ther Adv Musculoskelet Dis. 2016;8(6):225\u201335.","journal-title":"Ther Adv Musculoskelet Dis"},{"issue":"9","key":"9965_CR38","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1111\/bph.15024","volume":"178","author":"BL Langdahl","year":"2021","unstructured":"Langdahl BL. Overview of treatment approaches to osteoporosis. Br J Pharmacol. 2021;178(9):1891\u2013906.","journal-title":"Br J Pharmacol"},{"key":"9965_CR39","unstructured":"Higgins JPTTJ, Chandler J et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.5 (updated August 2024). Cochrane, 2024. Available from www.cochrane.org\/handbook"}],"container-title":["BMC Musculoskeletal Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12891-026-09965-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-026-09965-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12891-026-09965-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T04:17:01Z","timestamp":1783484221000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12891-026-09965-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,16]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["9965"],"URL":"https:\/\/doi.org\/10.1186\/s12891-026-09965-w","relation":{},"ISSN":["1471-2474"],"issn-type":[{"value":"1471-2474","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,16]]},"assertion":[{"value":"20 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"592"}}